MedTrace Logo

Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)

NCT05764317 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 409

Last updated 2024-04-19

No results posted yet for this study

Summary

This is a multi-centre, observational, ambispective study, which will retrospectively and prospectively collect clinical and socio-demographic data from medical records of patients with HTN and dyslipidemia initiated with SPC of amlodipine/atorvastatin/perindopril in real clinical settings.

A total of 80 general practitioners and outpatient cardiologists will participate in this non-interventional study 400 patients should be included in the study.

Conditions

  • Arterial Hypertension
  • HTN

Interventions

DRUG

Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg

a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation

DRUG

Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg

a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation

DRUG

Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg

a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation

Sponsors & Collaborators

  • Servier Russia

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2023-11-30
Completion
2024-02-20

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05764317 on ClinicalTrials.gov